- Home
- DXST vs COCP Comparison
DXST vs COCP Comparison
Compare DXST & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXST
- COCP
- Stock Information
- Founded
- DXST 2011
- COCP 2006
- Country
- DXST China
- COCP United States
- Employees
- DXST N/A
- COCP N/A
- Industry
- DXST
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- DXST
- COCP Health Care
- Exchange
- DXST NYSE
- COCP Nasdaq
- Market Cap
- DXST 18.7M
- COCP 15.4M
- IPO Year
- DXST 2025
- COCP N/A
- Fundamental
- Price
- DXST $1.16
- COCP $1.46
- Analyst Decision
- DXST
- COCP Strong Buy
- Analyst Count
- DXST 0
- COCP 1
- Target Price
- DXST N/A
- COCP $7.00
- AVG Volume (30 Days)
- DXST 36.5K
- COCP 15.8K
- Earning Date
- DXST 01-01-0001
- COCP 05-27-2025
- Dividend Yield
- DXST N/A
- COCP N/A
- EPS Growth
- DXST 13.11
- COCP N/A
- EPS
- DXST 0.14
- COCP N/A
- Revenue
- DXST $11,542,292.00
- COCP N/A
- Revenue This Year
- DXST N/A
- COCP N/A
- Revenue Next Year
- DXST N/A
- COCP N/A
- P/E Ratio
- DXST $8.91
- COCP N/A
- Revenue Growth
- DXST 22.18
- COCP N/A
- 52 Week Low
- DXST $0.85
- COCP $1.12
- 52 Week High
- DXST $5.74
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- DXST N/A
- COCP 46.70
- Support Level
- DXST N/A
- COCP $1.44
- Resistance Level
- DXST N/A
- COCP $1.79
- Average True Range (ATR)
- DXST 0.00
- COCP 0.19
- MACD
- DXST 0.00
- COCP 0.00
- Stochastic Oscillator
- DXST 0.00
- COCP 27.08
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).